<DOC>
	<DOC>NCT00380445</DOC>
	<brief_summary>Please note this study is not being conducted in the United States. The purpose of this study is to test the hypothesis that acute DPP-4 inhibition with vildagliptin improves fat and muscle metabolism in patients with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Must be able to complete a 3week washout of current antidiabetic medication Cannot take any medications which may alter gastric motility except for cardiac medication at a stable dose Must discontinue betablockers and lipid lowering drugs Blood glucose criteria must be met BMI in the range 3035 History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes Need for insulin within 3 months or patients on thiazolidinediones Patients taking a sulfonylurea or metformin who cannot safely discontinue medication for the duration of the study Significant concomitant disease or complications of diabetes Patients with any history of gastrointestinal surgery or positive gastrointestinal symptons High tryglycerides as defined by the protocol Smokers who cannot abstain from smoking during the treatment periods</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Vildagliptin, Type 2 diabetes</keyword>
</DOC>